share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  05/06 12:59
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.
Vivos Therapeutics, Inc. 是一家在納斯達克股票市場上市的特拉華州註冊公司，股票代碼爲VVOS。該公司於2024年5月3日報告稱，它認爲已恢復遵守納斯達克250萬美元的最低股東權益要求。在此之前，籌資活動於2023年11月和2024年2月完成，包括對普通股購買權證的修訂。該公司目前正在等待納斯達克對其合規狀況的確認。Vivos Therapeutics預計，納斯達克將監督其持續的合規情況，並承認需要籌集額外的股權資本以維持這種合規性。該公司還認識到無法籌集足夠資金的風險，這可能導致從納斯達克退市，並對其股價、交易能力、籌資能力和聲譽產生重大不利影響。
Vivos Therapeutics, Inc. 是一家在納斯達克股票市場上市的特拉華州註冊公司，股票代碼爲VVOS。該公司於2024年5月3日報告稱，它認爲已恢復遵守納斯達克250萬美元的最低股東權益要求。在此之前，籌資活動於2023年11月和2024年2月完成，包括對普通股購買權證的修訂。該公司目前正在等待納斯達克對其合規狀況的確認。Vivos Therapeutics預計，納斯達克將監督其持續的合規情況，並承認需要籌集額外的股權資本以維持這種合規性。該公司還認識到無法籌集足夠資金的風險，這可能導致從納斯達克退市，並對其股價、交易能力、籌資能力和聲譽產生重大不利影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息